- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cigna Refers to NCCN Guidelines for Oncology Coverage Decisions
The Cigna-NCCN collaboration will benefit about 12.5 million members.
As part of the company's coverage policy development, Cigna is using the NCCN Guidelines(R) and the NCCN Compendium(R) as references in the appropriate choice for the treatment of people with cancer in the United States.
Cigna is using National Comprehensive Cancer Network® (NCCN®) Content as a resource for oncology coverage policy development and updates for the company's more than 840,000 providers throughout the United States.
"Cigna recognizes the important role that NCCN has in establishing standards and guidance for care in the area of cancer screening, diagnosis, treatment, and surveillance," said Julie B. Kessel, MD, Cigna's Senior Medical Director for Coverage Policy.
Read the report: http://cnnmon.ie/1vuxXYw
Source: CNN Money
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
